Investor Alert: Pomerantz Law Firm Investigates Potential Securities Fraud at LENZ Therapeutics
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by Lenz Therapeutics, Inc. (NASDAQ: LENZ) and its officers or directors on behalf of investors. The investigation follows the company's second-quarter 2026 financial report released on August 11, which showed total revenue of $5.5 million—primarily driven by one-time licensing milestones rather than organic product sales. Lenz’s primary commercial eye drop, VIZZ, reported flat sales at $1.73 million with only a 9% volume increase quarter-over-quarter. On August 12, Bank of America downgraded the stock from 'Buy' to 'Neutral,' reducing its price target significantly due to slower-than-expected product launch performance for VIZZ. This downgrade led to a sharp decline in Lenz's stock price and potential investor losses.
